
GC-072: A Novel Therapeutic Candidate for Oral Treatment of Melioidosis and Infections Caused by Select Biothreat Pathogens

Comparative Immunogenicity and Efficacy of Thermostable (Lyophilized) and Liquid Formulation of Anthrax Vaccine Candidate AV7909

Repeat-Dose Toxicity Study of a Lyophilized Recombinant Protective Antigen-Based Anthrax Vaccine Adjuvanted With CpG 7909

Correlation Between Anthrax Lethal Toxin Neutralizing Antibody Levels and Survival in Guinea Pigs and Nonhuman Primates Vaccinated with the AV7909 Anthrax Vaccine Candidate

Licensure Strategy for Pre- and Post-Exposure Prophylaxis of Biothrax Vaccine: The First Vaccine Licensed Using the FDA Animal Rule

Randomized, Double-Blind, Active-Controlled Study Evaluating the Safety and Immunogenicity of Three Vaccination Schedules and Two Dose Levels of AV7909 Vaccine for Anthrax Post-Exposure Prophylaxis in Healthy Adults

Enhanced Early Innate and T Cell-Mediated Responses in Subjects Immunized with Anthrax Vaccine Adsorbed Plus CPG 7909 (AV7909)

Effect of Anthrax Immune Globulin on Response to BioThrax (Anthrax Vaccine Adsorbed) in New Zealand White Rabbits

